

Zilovertamab

Cat. No.:	HY-P99201
Target:	ROR
Pathway:	Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling ^[1] .
In Vitro	Zilovertamab (25 and 50 µg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation ^[1] . Zilovertamab (50 µg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level ^[1] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[1]
	Cell Line: CaOV3, CaOV3CisR, PEO1, and PEO4 cells
	Concentration: 25 and 50 µg/mL
	Incubation Time: 72 hours
	Result: Reduced the proliferation of CaOV3, CaOV3CisR and PEO1.
	Western Blot Analysis ^[1]
	Cell Line: CaOV3, CaOV3CisR, PEO1, and PEO4 cells
	Concentration: 50 µg/mL
	Incubation Time: 72 hours
	Result: Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level.

REFERENCES

[1]. Liu D, et, al. The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. *Pharmaceutics*. 2022 Apr 11;14(4):837.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA